文献速递泌尿男性生殖肿瘤

卡博替尼通过激活抗肿瘤先天免疫清除晚期小鼠前列腺癌

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.
PubMed 文献 · Cancer Discov · 2017-03-08

研究显示,酪氨酸激酶抑制剂卡博替尼可快速清除侵袭性、低分化的PTEN/p53缺陷小鼠前列腺癌,其机制与肿瘤细胞释放中性粒细胞趋化因子CXCL12和HMGB1、促使中性粒细胞浸润有关;抗体介导的粒细胞清除、HMGB1中和或CXCR4抑制剂普乐沙福阻断中性粒细胞趋化均可消除卡博替尼的肿瘤清除作用。

要点

  • 卡博替尼快速清除侵袭性PTEN/p53缺陷小鼠前列腺癌。
  • 肿瘤细胞释放CXCL12和HMGB1等中性粒细胞趋化因子增强。
  • 粒细胞清除、HMGB1中和或普乐沙福阻断趋化可消除肿瘤清除。

核心结论

  • 卡博替尼触发中性粒细胞介导的抗癌先天免疫反应,导致肿瘤清除。

研究设计与样本

  • 研究使用侵袭性、低分化的PTEN/p53缺陷小鼠前列腺癌模型。

主要发现

  • 卡博替尼快速清除侵袭性、低分化的PTEN/p53缺陷小鼠前列腺癌。
  • 卡博替尼与肿瘤细胞释放中性粒细胞趋化因子CXCL12和HMGB1增强相关,导致中性粒细胞大量浸润肿瘤。
  • 抗体介导的粒细胞清除、HMGB1中和或用CXCR4抑制剂普乐沙福阻断中性粒细胞趋化均可消除卡博替尼诱导的小鼠肿瘤清除。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial patients across several malignancies. Here, we show that cabozantinib rapidly eradicates invasive, poorly differentiated PTEN/p53-deficient murine prostate cancer. This was associated with enhanced release of neutrophil chemotactic factors from tumor cells, including CXCL12 and HMGB1, resulting in robust infiltration of neutrophils into the tumor. Critically, cabozantinib-induced tumor clearance in mice was abolished by antibody-mediated granulocyte depletion or HMGB1 neutralization or blockade of neutrophil chemotaxis with the CXCR4 inhibitor plerixafor. Collectively, these data demonstrate that cabozantinib triggers a neutrophil-mediated anticancer innate immune response, resulting in tumor clearance.Significance: This study is the first to demonstrate that a tyrosine kinase inhibitor can activate neutrophil-mediated antitumor innate immunity, resulting in invasive cancer clearance. Cancer Discov; 7(7); 750-65. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 653.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Patnaik A, Swanson KD, Csizmadia E, et al. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov. 2017. PMID: 28274958. doi:10.1158/2159-8290.CD-16-0778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。